Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAT-1604 in Advanced Solid Tumors
NCT06998173Phase 1Not yet recruiting
- Sponsor
- Danatlas Pharmaceutical Inc.
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of DAT-1604 in solid tumor (advanced stage) (4 arms), sponsored by Danatlas Pharmaceutical Inc. Primary endpoints: Safety and Tolerability at 12 months and Recommended Phase 2 Dose at 12 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
DAT-1604
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06998173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06998173.